Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phytosomal silymarin
- Development stage
- Unknown
- Lead developer
- Indena
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Phytosomal silymarin (commonly known by the brand name Siliphos) is a highly bioavailable formulation of silymarin—specifically silybin, the primary active flavonolignan of milk thistle (*Silybum marianum*)—complexed with phospholipids (primarily phosphatidylcholine). Developed by Indena, this phytosome technology significantly enhances the absorption and systemic bioavailability of silybin compared to conventional milk thistle extracts. Phytosomal silymarin is widely utilized as a hepatoprotective and antioxidant nutraceutical. It has been investigated in clinical trials for various conditions, including non-alcoholic steatohepatitis (NASH), hepatitis C, and as an adjunctive therapy in oncology (such as prostate, breast, and lung cancers) due to its anti-inflammatory, anti-fibrotic, and chemopreventive properties.
- Brand names
- SiliphosSilipide
- Other names
- milk thistle phytosomephytosomal silybinsilibinin phytosomesilybin phytosomesilybin-phosphatidylcholine complexsilybin-phospholipid complexsilymarin phytosome
02
Targets
GCK (Glucokinase)IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)RPS6KA3 (RSK2)SKP2UCP2 (Uncoupling protein 2)
Beyond the preview
Go deeper on phytosomal silymarin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phytosomal silymarin.